Clinical Trial Update: Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating an autologous tumor cell-TLR9 agonist vaccination for metastatic colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Autologous tumor cell-TLR9 agonist vaccine

Snippet

Sponsor: Stanford University | Conditions: Colorectal Neoplasms, Anal, Colon, and Rectal Cancers | Phase 1 | Status: WITHDRAWN